39.99
Xenon Pharmaceuticals Inc stock is traded at $39.99, with a volume of 855.57K.
It is up +0.88% in the last 24 hours and up +10.44% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$39.64
Open:
$39.95
24h Volume:
855.57K
Relative Volume:
1.03
Market Cap:
$3.08B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-14.59
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+1.11%
1M Performance:
+10.44%
6M Performance:
+27.36%
1Y Performance:
-2.96%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
XENE
Xenon Pharmaceuticals Inc
|
39.99 | 3.06B | 13.17M | -199.06M | -156.53M | -2.74 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-03-25 | Resumed | Wells Fargo | Overweight |
May-07-25 | Initiated | Chardan Capital Markets | Buy |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Oct-10-24 | Resumed | Raymond James | Outperform |
Oct-01-24 | Initiated | H.C. Wainwright | Buy |
Jan-04-24 | Initiated | Citigroup | Buy |
Dec-08-23 | Initiated | Robert W. Baird | Outperform |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-14-22 | Initiated | Goldman | Buy |
Dec-12-22 | Initiated | Cowen | Outperform |
Nov-28-22 | Initiated | Wells Fargo | Overweight |
Oct-19-22 | Initiated | Raymond James | Outperform |
Aug-29-22 | Initiated | BofA Securities | Buy |
Jul-21-22 | Initiated | JP Morgan | Overweight |
Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-02-20 | Initiated | SVB Leerink | Outperform |
Jul-21-20 | Initiated | Needham | Buy |
Jun-01-20 | Resumed | Jefferies | Buy |
Mar-25-20 | Initiated | Wedbush | Outperform |
Jan-08-20 | Initiated | William Blair | Outperform |
Sep-20-19 | Initiated | Guggenheim | Buy |
Aug-08-18 | Reiterated | Stifel | Buy |
Mar-13-17 | Initiated | Jefferies | Buy |
Oct-21-16 | Initiated | Stifel | Buy |
Sep-26-16 | Initiated | Guggenheim | Buy |
Apr-14-16 | Reiterated | Jefferies | Buy |
Oct-30-15 | Resumed | Jefferies | Buy |
Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Will Xenon Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Update & Trade Opportunity Analysis - newser.com
Published on: 2025-10-13 08:53:34 - newser.com
Xenon Pharmaceuticals Inc.’s volatility index tracking explainedMarket Performance Report & Fast Gain Stock Trading Tips - newser.com
Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsWeekly Trade Recap & Entry Point Confirmation Alerts - newser.com
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance
Leerink Partners Remains a Buy on Xenon (XENE) - The Globe and Mail
Research Analysts Issue Forecasts for XENE FY2025 Earnings - MarketBeat
What is Bloom Burton’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Will Xenon Pharmaceuticals Inc. stock attract ESG investorsDay Trade & Free Weekly Watchlist of Top Performers - newser.com
Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat
Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat
Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat
XENE: Chardan Capital Maintains Buy Rating with $55 Price Target | XENE Stock News - GuruFocus
Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq
Transcript : Xenon Pharmaceuticals Inc.Special Call - MarketScreener
Will Xenon Pharmaceuticals Inc. stock recover after recent dropJobs Report & Verified Swing Trading Watchlist - newser.com
Is it time to cut losses on Xenon Pharmaceuticals Inc.Market Growth Summary & Safe Capital Investment Plans - newser.com
Xenon Pharmaceuticals Inc. $XENE Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Xenon Pharmaceuticals announces executive changes - MSN
HighMark Wealth Management LLC Has $817,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. stock chart pattern explainedWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Will Xenon Pharmaceuticals Inc. stock maintain growth storyGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 25,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals Hits Day High with Strong 9.94% Intraday Surge - Markets Mojo
Published on: 2025-10-01 07:26:08 - newser.com
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO |
Oct 01 '25 |
Sale |
40.16 |
25,000 |
1,004,000 |
31,302 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):